Zimbabwe has declined a major US health deal valued at $367m (272 million pounds) over five years over Washington's request for confidential data.
The decision came to light after a official document from December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesperson later stated that the US was seeking biological samples for scientific study and commercial gain but was not willing to guarantee the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more dialogue to reach a agreement acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a similar case in Kenya, where a high court suspended a related deal with the US following legal challenges were filed about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing government-to-government agreements to enhance transparency and accountability.
According to statements, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research with no assurance that the end products would be available to our citizens if a new health crisis emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks already set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This system is intended to ensure that when a country provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration could be arranged in a manner that respects the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but suggested that negotiations need to persist since a large portion of the nation's HIV programmes depended on external financing.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group said.
The situation emphasises the ongoing debate between accepting crucial international aid and protecting a country's data in an increasingly interconnected world.